AB011. SOH21AS231. Is radiomics a feasible alternative to OncotypeDXTM recurrence score testing?—a systematic review and meta-analysis

Matthew Gerard Davey, Peter Francis McAnena, Aoife Lowery, Michael Kerin

Department of Surgery, The Lambe Institute for Translational Research, National University of Ireland, Galway, Ireland

Background: Genomic signatures such as OncotypeDXTM recurrence score (RS) aid adjuvant therapeutic decision in early stage estrogen receptor positive breast cancer. Radiomics involves the extraction of quantitative characteristics from tumour tissue to aid diagnosis, prognostication and therapeutic decision making. We aimed to perform a systematic review of current evidence evaluating the compatibility of radiomics and RS testing.

Methods: A systematic review and meta-analysis was performed in accordance to PRISMA guidelines. Retrospective cohort studies comparing radiomic tumour analyses and RS were identified. Receiver operating characteristics (ROC) and area under curve (AUC) were determined from low risk (RS <18) vs intermediate-high risk (>18) and low-intermediate risk (RS <30) and high risk (RS >30). Log rate ratios (LnRR) and standard error were determined from AUC and 95% confidence intervals (CI).

Results: Five studies including 626 patients met inclusion criteria; the mean age at diagnosis was 52.3 years. Mean RS was 15 (range, 1–75), and 286 with RS <18, 201 with RS 18–30 and 55 with RS >30. Radiomic testing was comparable with RS for differentiating cancers with RS <18 vs RS >18 (RR: 0.93, 95% CI: 0.85–1.00, P=0.010, heterogeneity (I²) =0%). However, radiomics was less accurate for differentiating those with RS <30 vs RS >30 (RR: 0.76, 95% CI: 0.68–0.84, P<0.001, I²=0%).

Conclusions: Radiomic tumour analysis is comparable to genomic assays currently included in breast cancer patient management. Future evaluation should incorporate radiomic testing into practice to enhance diagnostics, prognostication as well as therapeutic decision making in those diagnosed with breast cancer.

Keywords: Breast cancer; radiomics; genomics; personalised medicine; precision medicine

Acknowledgments

Funding: None.

Footnote

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/map-21-ab011). AL serves as an unpaid editorial board member of Mesentery and Peritoneum. The other authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

doi: 10.21037/map-21-ab011

Cite this abstract as: Davey MG, McAnena PF, Lowery A, Kerin M. Is radiomics a feasible alternative to OncotypeDXTM recurrence score testing?—a systematic review and meta-analysis. Mesentery Peritoneum 2021;5:AB011.